Skip to content
FrontierPicks

Dormant

VRNS · Varonis Systems, Inc.

Last analysed ·

Against its published line

Nothing is through its line on this close.

How to read this

The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 21 August 2026; a dot LEFT of the mark has closed through its line.

Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.

How a pick resolves

VRNSVaronis Systems, Inc.
$41.00
$41.23
+0.6%

Current thesis

Varonis Systems' takeover story depends on reported Proofpoint talks producing a signed offer above the September 18 close of $47.56. A weekly close below $41 or confirmed termination of the talks invalidates the thesis.

Kill line

A weekly close below $41 breaks the August price structure referenced by the 2026-08-21 close of $41.23; confirmed termination of Proofpoint talks or agreed consideration at or below the 2026-09-18 close of $47.56 separately defeats the premium thesis.

Pick status

Open commitment scored if the kill line above fires How this is scored →

Latest analysis and events for VRNS —

As of 19 September 2026, the latest FrontierPicks analysis for Varonis Systems, Inc. (VRNS): Varonis Systems' takeover story depends on reported Proofpoint talks producing a signed offer above the September 18 close of $47.56. A weekly close below $41 or confirmed termination of the talks invalidates the thesis.

Kill line: A weekly close below $41 breaks the August price structure referenced by the 2026-08-21 close of $41.23; confirmed termination of Proofpoint talks or agreed consideration at or below the 2026-09-18 close of $47.56 separately defeats the premium thesis.

Current Thesis

Varonis Systems' takeover story depends on reported Proofpoint talks producing a signed offer above the September 18 close of $47.56; a weekly close below $41 invalidates the price thesis. Reuters reported the discussions on 2026-09-02, but the reporting reviewed through 2026-09-20 did not establish definitive terms or an announcement date. The distinction remains material: reported negotiations establish interest, not an acquisition price. Reuters, September 2

The September 5 thesis has gained a higher market close and a new analyst endorsement: the shares closed at $47.56 on 2026-09-18, versus $46.09 on 2026-09-04, and Benzinga reported Needham's increase to a $55 price target on 2026-09-09. As an inference, the narrative is maturing — the named-counterparty report dates to 2026-09-02, the September 9 management appearance has passed, and the available update still lacks transaction terms. That classification does not establish weaker participation; no current fund-flow evidence supports that claim.

Bullish and bearish views on Varonis Systems, Inc.

The model's bull view on Varonis Systems, Inc. (VRNS), in brief: A named counterparty supports the thesis. The bear view: The premium remains unspecified. Reuters' 2026-09-02 report supplied no agreed consideration, and no definitive terms were identified in the reporting reviewed through 2026-09-20. An agreement at or below the September 18 close of $47.56 would fail the premium thesis even if an… Both cases follow in full.

Bull Case

  • A named counterparty supports the thesis. Reuters' 2026-09-02 reporting identified Thoma Bravo-owned Proofpoint as the prospective acquirer. A signed agreement above the 2026-09-18 market close of $47.56 would resolve the specific premium thesis; reporting that talks ended would defeat it. Reuters, September 2
  • Standalone results support the business case. Varonis' 2026-07-28 results reported second-quarter revenue of $180.0 million against $176.8 million consensus and raised full-year revenue guidance to $735–739 million. These are operating results and company guidance, not evidence of a bidder's willingness to pay.
  • Management described recovered customer contracts. At the 2026-09-09 Citi conference, Chief Financial Officer Guy Melamed said some delayed contracts had closed before the second-quarter report and supported the guidance increase. His expectation that more delayed contracts would close during the third quarter remains unverified; another reported deferral would contradict it. September 9 conference transcript

Bear Case

  • The premium remains unspecified. Reuters' 2026-09-02 report supplied no agreed consideration, and no definitive terms were identified in the reporting reviewed through 2026-09-20. An agreement at or below the September 18 close of $47.56 would fail the premium thesis even if an acquisition proceeded. Reuters, September 2
  • Conversions inflate headline recurring growth. The 2026-07-28 results reported software-as-a-service (SaaS) annual recurring revenue (ARR) of $726.0 million, growing 52% year over year; growth excluding perpetual-license conversions was 25%. The latter measure provides the cleaner test of underlying expansion.
  • Product monetization remains insufficiently quantified. At the 2026-09-09 conference, Melamed declined to quantify newer products' effect on average selling prices because the sample and financial impact were insufficient. The available evidence therefore supports no numerical claim about an artificial-intelligence revenue uplift. September 9 conference transcript

Setup & Price Structure

The supplied adjusted daily series records a $47.56 close on 2026-09-18, a three-month price increase of 45.4%, and a 14-day relative strength index of 63.7. The same snapshot places the shares 24.9% below their $63.31 annual high. These are measured price observations; they do not establish short covering or a crowded shareholder base.

The September 18 close remains above the August 13 intraday high of $45.81 identified in the earlier coverage. The deeper structural reference remains the August 21 close of $41.23 and the previously published $41 weekly invalidation threshold. A weekly close below $41 would break that August reference area and invalidate the takeover-supported price structure.

The observable attention evidence is the September 2 takeover reporting followed by Needham's September 9 target increase to $55, reported by Benzinga. Current short interest, retail-flow measurements, moving-average levels and dated insider transactions are missing from the available evidence. Those observations are insufficient to establish crowding or expanding participation.

Catalyst Calendar (next 30 days)

  • 2026-09-30 — Timing checkpoint, not an announcement date. The September 3 Reuters account relayed by Private Equity Wire described a possible announcement in the coming weeks. September 30 remains the earlier dossier's analytical checkpoint; no agreement by then would weaken its near-term timing premise, without proving negotiations had ended. No confirmed transaction or earnings date was identified for 2026-09-20 through 2026-10-20.
  • ~2026-10-27, estimated — Third-quarter results. MarketBeat lists this date as unconfirmed and estimated from historical reporting schedules. This later event matters if negotiations remain unresolved: the July 28 company outlook called for quarterly revenue of $185–188 million, making revenue below $185 million a concrete failure of the operating fallback. MarketBeat earnings calendar

The company scheduled its Citi presentation for 2026-09-09; that calendar event has elapsed and supplies no future deadline for transaction disclosure. Varonis conference announcement, August 10

What Would Change Our Mind

Loss of the August price structure would end the market thesis: a weekly close below $41 would breach the threshold associated with the August 21 reference close of $41.23. A company announcement or credible report that Proofpoint negotiations ended would separately break the named-counterparty thesis. A signed agreement offering no more than the September 18 close of $47.56 would also fail the proposed premium outcome.

A definitive agreement above $47.56 would establish that outcome; it would not establish eventual completion. For the standalone fallback, third-quarter revenue below the $185 million lower end of July 28 guidance would contradict management's operating outlook. September ending without an agreement would weaken the timing case, while silence alone would establish neither continuing talks nor their collapse.

Correlation Notes

This remains a single-name transaction setup. Reuters' 2026-09-02 report identifies a specific prospective counterparty, while the supplied September 18 snapshot contains no matched cybersecurity-index return series. The available sample cannot establish a sector correlation or show that a broader group move explains the rally.

Cybersecurity and artificial-intelligence data security describe operating exposure, not measured return relationships. Management discussed those product markets at the 2026-09-09 Citi conference, but its unquantified product commentary does not establish that broader artificial-intelligence spending will determine the transaction outcome. September 9 conference transcript

Notes

  • No definitive agreement, price or 8-K exists as of 2026-09-05; the Proofpoint talks are press-reported only and all parties declined or did not comment.
  • Total SaaS ARR growth is flattered by perpetual-to-SaaS conversions: +52% YoY in Q2 2026 versus +25% excluding conversions. The ex-conversions line is the clean one.
  • Q2 2026 non-GAAP operating income was $3.7M while the GAAP result stayed a loss; the valuation debate runs on ARR and free cash flow, not EPS.
  • The stock moves on headlines rather than trending: single sessions of 9%+ occurred on 2026-08-13 with no company release and on 2026-09-02 with a volatility halt.
  • Proofpoint is a Thoma Bravo portfolio company, so any transaction is gated by leveraged-financing conditions and by overlap review of two data-protection stacks.

Related · shared themes